Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Ligand Pharmaceuticals (LGNYZ) over the last 9 years, with Q3 2025 value amounting to $135000.0.

  • Ligand Pharmaceuticals' Other Accumulated Expenses changed N/A to $135000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $135000.0, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2024, which is N/A changed from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Other Accumulated Expenses stood at $135000.0 for Q3 2025.
  • Ligand Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $1.3 million for Q4 2024, and its period low was $135000.0 during Q3 2025.
  • Moreover, its 4-year median value for Other Accumulated Expenses was $457000.0 (2022), whereas its average is $651600.0.